Fred Hutchinson
Fred Hutchinson Cancer Center is an NCI-designated nonprofit cancer research and treatment institution in Seattle treating 50+ cancer types across 750+ clinical trials, serving as UW Medicine's cancer program and generating revenue through patient care, research grants, and philanthropy.
- Company typePrivate
- Founded1975
- HeadquartersSeattle, United States
- Headcount1,001–5,000
- GTM typeB2C
- OfferingServices
What Fred Hutchinson does
Fred Hutchinson Cancer Center is an independent nonprofit 501(c)(3) cancer research and treatment institution founded in 1975 in Seattle, Washington, and operating across clinical locations in Seattle, Kirkland, Bellevue, and Issaquah. It serves as UW Medicine's cancer program and is designated as an NCI Comprehensive Cancer Center, recognized by U.S. News & World Report as the top cancer hospital in the Pacific Northwest. The organization treats patients across more than 50 cancer types, runs over 750 active clinical trials, and employs 5,001–10,000 staff. Its clinical portfolio spans immunotherapy, blood and marrow transplantation (a modality Fred Hutch pioneered), medical oncology, radiation oncology, surgical oncology, proton therapy, CRS-HIPEC, radiology, and supportive care services. Patient-facing infrastructure includes the Epic MyChart portal and mobile app, telehealth services, and a regional mammogram van program.
The center's research operations span eight divisions covering basic sciences, clinical research, human biology, public health sciences, vaccine and infectious disease, and translational therapeutics, with active programs in CRISPR gene therapy, monoclonal antibody development (including EBV antibodies targeting gp350/gp42), liquid biopsy tools (PEARL for preeclampsia, Precede Bio Insight for solid tumors), and pandemic preparedness research. Strategic technology partnerships include AWS Amazon Bio Discovery for AI-driven antibody design and a memorandum of understanding with the Abu Dhabi Department of Health to leverage population-scale genomic data. Revenue is generated through patient care services reimbursed by Medicare, Medicaid, and private insurance; research grants from the NCI, American Cancer Society, and the Paul G. Allen estate's Fund for Science and Technology; and philanthropy through events such as Base 2 Space and Obliteride.
Fred Hutchinson firmographics
Firmographics- Name
- Fred Hutchinson
- Legal name
- Fred Hutchinson Cancer Center
- Website
- https://fredhutch.org
- Company type
- Private
- Founded year
- 1975
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Fred Hutchinson Cancer Center is an NCI-designated nonprofit cancer research and treatment institution in Seattle treating 50+ cancer types across 750+ clinical trials, serving as UW Medicine's cancer program and generating revenue through patient care, research grants, and philanthropy.
- Ownership category
- akta.pro rank
Fred Hutchinson industry classification
Industry- Product category
- Cancer Treatment and Research Services
- NAICS
- Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Offices of Physicians (62111), Diagnostic Imaging Centers (621512)
- SIC
- Services-Hospitals (8060), Services-Specialty Outpatient Facilities, Nec (8093), Services-Offices & Clinics Of Doctors Of Medicine (8011)
- akta.pro primary industry
- Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI)
- akta.pro secondary industries
- Oncology & Cancer Specialty Hospitals (HLAFAHAC), Medical Oncology (HLAKAFAB), Advanced Imaging & Specialty Radiology Centers (PET/CT, Nuclear Medicine, Interventional Radiology) (HLAFAKAB)
Keywords
Where Fred Hutchinson is headquartered
LocationHeadquarters
- HQ city
- Seattle
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
Fred Hutchinson business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Patient Care Services: Fred Hutch provides comprehensive cancer treatment services including chemotherapy, immunotherapy, radiation oncology, surgical oncology, proton therapy, blood and marrow transplant, and supportive care services. Revenue is generated through patient services, insurance reimbursements, and facility fees.
- Research Grants and Funding: Fred Hutch receives significant funding through research grants from organizations including the National Cancer Institute, American Cancer Society, Fund for Science and Technology (Paul G. Allen estate), and various pharmaceutical and foundation sponsors.
- Philanthropy and Donations: Fundraising activities including Base 2 Space stair climb event (raised record $1.16 million in 2025, bringing 10-year total to more than $5.8 million), Obliteride cycling event, direct donations, and planned giving programs.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Pay-as-you-go | MyChart Medical Advice Message Billing |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels6 records
Fred Hutchinson product offering
Product offeringCore offering
Fred Hutchinson Cancer Center is an independent nonprofit organization that delivers comprehensive cancer treatment services—including immunotherapy, blood and marrow transplantation, medical, radiation and surgical oncology, proton therapy, and supportive care—while operating more than 750 active clinical trials and conducting laboratory research across eight scientific divisions. It functions as both an NCI-designated Comprehensive Cancer Center and the cancer program for UW Medicine, translating laboratory discoveries into clinical treatments.
Product overview
Fred Hutchinson Cancer Center is a comprehensive cancer research and clinical care institution offering a unified platform of treatment services, prevention programs, patient engagement tools, and research capabilities. The core clinical offerings include immunotherapy, blood and marrow transplant, medical oncology, radiation oncology, surgical oncology, proton therapy, and over 750 active clinical trials. Patient-facing digital services include the MyChart patient portal (web and mobile app) for accessing medical records, scheduling, and care team communication. Research operations span eight scientific divisions covering basic sciences through translational therapeutics. The institution does not operate a traditional software product business; rather, it provides clinical services, conducts scientific research, and collaborates on technology initiatives such as AI-driven drug discovery and genomics programs.
Differentiator
Problem solved
Functional benefit
Products and services
- Immunotherapy for Cancer
Quantifiable outcome
- 27 of 28 stem cell transplant participants survived at least one year without severe rejection symptoms in pooled umbilical cord blood trial
- +2 more outcomes
Companies that use Fred Hutchinson
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
Fred Hutchinson technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability14 records
Feature6 records
Fred Hutchinson partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- UCSF, Mount Sinai, Institut PasteurcoreFred Hutch researchers collaborated with UCSF, Mount Sinai, and Institut Pasteur on a study published in Cell Host & Microbe discovering that a single amino acid change in coronavirus protein Orf9b determines viral spillover potential from bats to humans.
- Abu Dhabi Department of Health and Abu Dhabi Public Health CentercoreMemorandum of understanding signed to collaborate on cancer research and personalized prevention. The partnership combines Abu Dhabi's clinical and genomic data infrastructure, AI capabilities, and governed data environments with Fred Hutch's globally recognized research expertise. Collaboration leverages Abu Dhabi's smart health system, liquid biopsy program, AI-driven early cancer detection, and the world's largest clinically integrated population genomics program with nearly one million sequenced genomes.
- Deverra TherapeuticscoreResearchers from Fred Hutchinson Cancer Center collaborated on clinical trials of dilanubicel, a pooled umbilical cord blood stem cell product developed by Deverra Therapeutics. The product combines blood stem cells from six to eight different cord blood units for improved transplant outcomes.
- Precede BiosciencescoreFred Hutch collaborated with Precede Biosciences on studies presented at AACR 2026 demonstrating the assay's ability to predict therapeutic response and reveal resistance mechanisms in breast and prostate cancer using Precede Bio Insight liquid biopsy product.
- Amazon Web ServicescoreFred Hutch Cancer Center is an early adopter of Amazon Bio Discovery, an AI-powered drug discovery platform. The platform provides access to biological foundation models and AI agents for evaluating antibody candidates. Fred Hutch joins Memorial Sloan Kettering, Bayer, Broad Institute, and Voyager Therapeutics as early adopters.
- Fight CRC and Pfizer (via NCCN Oncology Research Program)minorNCCN Oncology Research Program awarded grants to projects focused on optimizing biomarker-directed therapy in metastatic colorectal cancer, with collaborations involving Fight CRC and Pfizer. Projects aim to improve molecular profiling, reduce testing barriers, and increase access to personalized treatment.
- UW MedicinecoreFred Hutch is an independent organization that also serves as the cancer program for UW Medicine. The partnership provides integrated cancer care with shared faculty, research collaborations, and coordinated patient care across both institutions.
- EvergreenHealth and OverlakecoreFred Hutch provides cancer care on the Eastside of King County in partnership with EvergreenHealth and Overlake, with locations in Kirkland, Bellevue, and Issaquah designed to meet patients where they are.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Fred Hutchinson competitors and assessment
Company assessmentDirect peers
- Memorial Sloan Kettering Cancer Center: NCI-designated Comprehensive Cancer Center in New York combining biomedical research with clinical oncology and a heavy immunotherapy focus. Comparable as a direct peer in scale, NCI designation, and translational research model; co-early adopter with Fred Hutch of the AWS Amazon Bio Discovery AI platform.
- MD Anderson Cancer Center: University of Texas–affiliated NCI Comprehensive Cancer Center, the largest U.S. cancer center by operating revenue. Comparable as the leading reference institution for combined research, clinical trials, and multidisciplinary cancer care, with overlapping services in immunotherapy, radiation oncology, and proton therapy.
- Dana-Farber Cancer Institute: Harvard Medical School–affiliated NCI Comprehensive Cancer Center with a parallel model of research-driven clinical care and a heavy emphasis on immunotherapy and precision oncology. Directly comparable in mission and translational research depth; collaborated with Fred Hutch on the Precede Bio Insight AACR 2026 launch.
- Stanford Cancer Institute: Stanford Medicine's NCI-designated Comprehensive Cancer Center combining translational research, clinical trials, and precision oncology. Comparable as a West Coast academic peer with similar technology-forward research orientation and clinical trial volume.
- UCSF Helen Diller Family Comprehensive Cancer Center: NCI-designated Comprehensive Cancer Center at UCSF with a parallel model combining research across immunology, genomics, and population science with multidisciplinary clinical care. Directly comparable as a Northern California academic cancer center with overlapping research and clinical focus.
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center: Johns Hopkins–affiliated NCI Comprehensive Cancer Center operating a research-clinical integration model similar to Fred Hutch's, with strong programs in immunotherapy, BMT, and translational science. Comparable in mission and academic orientation.
- City of Hope Comprehensive Cancer Center: NCI-designated Comprehensive Cancer Center in Southern California with deep expertise in BMT, immunotherapy, and translational research. Comparable as a research-intensive academic cancer center with overlapping hematologic oncology and cellular therapy programs.
- Roswell Park Comprehensive Cancer Center: The first NCI-designated Comprehensive Cancer Center in the U.S., operating a combined research and clinical model focused on immunotherapy, BMT, and population sciences. Comparable as a longstanding nonprofit cancer center with parallel mission and grant-funding profile.
Broad incumbents
- Mayo Clinic Comprehensive Cancer Center: Massive multi-specialty academic medical system with an NCI Comprehensive Cancer Center program embedded within a much broader clinical enterprise. Comparable in cancer research and clinical depth but materially larger and more diversified than Fred Hutch's cancer-only focus.
Regional players
- Seattle Children's Hospital: Pediatric academic health system in Seattle sharing clinical workforce dynamics and joint unionization activity with Fred Hutch and UW Medicine. Comparable as a regional peer where Seattle-area clinical labor and partnership dynamics intersect.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Fred Hutchinson social profiles
Digital presenceFred Hutchinson financial estimates
Financial estimateRevenue estimate
Valuation estimate
Fred Hutchinson leadership team
Management profileNumber of profiles
Profiles8 records
Fred Hutchinson funding detail
Funding detailFunding overview
Funding rounds5 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Fred Hutchinson M&A and investment
M&A and investmentM&A
Investments4 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Fred Hutchinson
What does Fred Hutchinson do?
Fred Hutchinson Cancer Center is an independent nonprofit organization that delivers comprehensive cancer treatment services—including immunotherapy, blood and marrow transplantation, medical, radiation and surgical oncology, proton therapy, and supportive care—while operating more than 750 active clinical trials and conducting laboratory research across eight scientific divisions. It functions as both an NCI-designated Comprehensive Cancer Center and the cancer program for UW Medicine, translating laboratory discoveries into clinical treatments.
Is Fred Hutchinson a public or private company?
Fred Hutchinson is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was Fred Hutchinson founded?
Fred Hutchinson was founded in 1975. It employs 1,001 to 5,000 people.
Where is Fred Hutchinson based?
Fred Hutchinson is headquartered in Seattle, United States, in the North America region.
How does Fred Hutchinson make money?
Three revenue lines are on record. Patient Care Services are the primary driver. The others are research Grants and Funding and philanthropy and Donations.
Who are Fred Hutchinson's main competitors?
Direct peers on record are Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, Dana-Farber Cancer Institute, Stanford Cancer Institute, UCSF Helen Diller Family Comprehensive Cancer Center, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, City of Hope Comprehensive Cancer Center and Roswell Park Comprehensive Cancer Center. Mayo Clinic Comprehensive Cancer Center is listed as a broad incumbent. Seattle Children's Hospital is listed as a regional player.
Does Fred Hutchinson have an API?
No public API is recorded for Fred Hutchinson.
What industry is Fred Hutchinson in?
Fred Hutchinson's product category is Cancer Treatment and Research Services. Its primary akta.pro industry code is HLAFABAI, Ambulatory Oncology Centers (Outpatient Chemo/Radiation), with a secondary code of HLAFAHAC, Oncology & Cancer Specialty Hospitals. Its NAICS code is 622310 and its SIC code is 8060.